Department Of Cardiology 5
201. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
202. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
203. Actual issues of secondary prevention of liver cancer in Kazakhstan
204. Combined Use of Inhaled and Intravenous Colistin in a Patient with Acute Lymphoblastic Leukemia Complicated by Multi-Organ Failure and Sepsis: A Case Report
205. Medico-social aspects of hepatocellular carcinoma
206. Correction to: Mitochondrial respiratory pathways in immature rat heart tissue using different cardioplegic solutions (General Thoracic and Cardiovascular Surgery, (2024), 10.1007/s11748-024-02097-9)
207. Mitochondrial respiratory pathways in immature rat heart tissue using different cardioplegic solutions
208. Data Resource Profile: The Global Health and Population Project on Access to Care for Cardiometabolic Diseases (HPACC)
209. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
210. Assessing risk factors for heart disease using machine learning methods
211. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases : Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS, the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN, and the European Society of Vascular Medicine (ESVM)
212. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension
213. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC
214. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC
215. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
216. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
217. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
218. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC
219. The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990–2021: a cross-country systematic analysis with forecasts to 2050
220. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC
221. SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI
222. SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI
223. SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI
224. SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI
225. SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI
226. SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI
227. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
228. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
229. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
230. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
231. Burden of disease scenarios by state in the USA, 2022–50: a forecasting analysis for the Global Burden of Disease Study 2021
232. Burden of disease scenarios by state in the USA, 2022–50: a forecasting analysis for the Global Burden of Disease Study 2021
233. The burden of diseases, injuries, and risk factors by state in the USA, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
234. The burden of diseases, injuries, and risk factors by state in the USA, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
235. The burden of diseases, injuries, and risk factors by state in the USA, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
236. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019
237. Artificial Intelligence-Augmented Propensity Score, Cost Effectiveness and Computational Ethical Analysis of Cardiac Arrest and Active Cancer with Novel Mortality Predictive Score
238. The Responsible Health AI Readiness and Maturity Index (RHAMI): Applications for a Global Narrative Review of Leading AI Use Cases in Public Health Nutrition
239. The Responsible Health AI Readiness and Maturity Index (RHAMI): Applications for a Global Narrative Review of Leading AI Use Cases in Public Health Nutrition
240. Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience
241. Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience
242. Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience
243. Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience
244. Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience
245. Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology
246. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)
247. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)
248. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)
249. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)
250. Socioeconomic disparities in physical activity, sedentary behavior and sleep patterns among 6- to 9-year-old children from 24 countries in the WHO European region
1 3 4 5 6 7 9